Background: We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ ritonavir 600/100 mg twice daily. Methods: Open-label, randomized pilot study in HIVinfected patients on darunavir/ritonavir 600/100 mg twice daily (viral load <50 copies/ml; darunavir vIQ >2). Thirty patients were randomized to darunavir/ritonavir 900/100 mg once daily (once-daily group, n=15) or 600/100 mg twice daily (twice-daily group, n=15). Viral load, blood chemistry, and darunavir and ritonavir trough plasma concentrations (C trough ) were determined up to 48 weeks. If the darunavir vIQ fell to <1.5, the dosage was switched to 600/100 mg twice daily. The primary end point was the percentage of 48-week treatment failure.
Darunavir is the latest HIV protease inhibitor to enter the therapeutic arsenal. Compared with other protease inhibitors, darunavir has demonstrated higher binding affinity for the HIV protease. This property confers potent intrinsic antiretroviral activity and a higher genetic barrier against the development of viral resistance [1, 2] . Like other protease inhibitors, darunavir undergoes extensive metabolism by the CYP3A4 isoform of cytochrome P450 [3] in the liver and intestinal lumen. Therefore, in order to enhance the pharmacokinetic profile of darunavir, it must be coadministered with low doses of ritonavir. At the approved dosage of darunavir/ritonavir for antiretroviral-experienced patients of 600/100 mg twice daily, darunavir concentrations at the end of the dosing interval remain far above the proteinbinding-corrected inhibitory concentration (IC 50 ) for viral strains resistant to other PIs [4, 5] .
The clinical usefulness of darunavir for salvage therapy in treatment-experienced HIV-infected patients was demonstrated in the POWER 1 and 2 studies [6] . In these trials, patients failing other protease-inhibitorbased regimens were randomized to receive salvage therapy containing darunavir/ritonavir (darunavir arm) or another investigator-selected control protease inhibitor (control arm). These trials included a dose-finding phase, in which patients in the darunavir arm were randomly assigned to take one of four different darunavir/ritonavir doses during the first 24 weeks (400/100 mg once
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daily, 800/100 mg once daily, 400/100 mg twice daily or 600/100 mg twice daily) [7] . Overall, patients assigned to darunavir/ritonavir showed better rates of virological and immunological response than patients allocated to the control arm, with the 600/100 mg twice daily dosage leading to the highest response at week 24. The 600/100 mg twice daily dosage was therefore selected for further investigation and was the one fixed when the drug was eventually licensed by the regulatory authorities for the treatment of antiretroviral-experienced HIVinfected patients [3] . However, recent interest in oncedaily dosing of darunavir/ritonavir has emerged because it offers the hope that this schedule might improve treatment convenience, especially for patients receiving other once-daily antiretroviral agents. Additionally, the oncedaily regimen might ameliorate possible side effects related to the use of ritonavir, including gastrointestinal disturbances and lipid abnormalities. Antiretroviral therapy with once-daily darunavir/ ritonavir has been evaluated in several clinical scenarios. For treatment-naive patients, the ARTEMIS study showed high efficacy for darunavir/ritonavir 800/100 mg once daily [8] . Moreover, once-daily darunavir/ritonavir showed a more favourable safety profile, with fewer treatment discontinuations owing to gastrointestinal disturbances and less increase in triglyceride or total cholesterol levels compared with lopinavir/ritonavir-based antiretroviral therapy. For patients with extensive prior antiretroviral experience, retrospective analyses of only those POWER trial participants with limited darunavir resistance at baseline showed comparable virological and immunological response in patients treated with darunavir/ ritonavir at dosages of either 800/100 mg once daily or 600/100 mg twice daily [9, 10] . Also, the MONET study randomized patients with no prior history of treatment failure and full virological suppression to a treatment-maintenance strategy consisting of darunavir/ritonavir 800/100 mg once daily, either as monotherapy or with two nucleoside reverse transcriptase inhibitors [11] . Results at 48 weeks showed that oncedaily darunavir/ritonavir was well tolerated and had extremely high efficacy in maintaining complete viral suppression in this population of patients. Finally, encouraging results from the ODIN trial, in which patients with limited antiretroviral-experience and no darunavir resistance-associated mutations (RAMs) were randomized to receive once or twice daily darunavir/ritonavir, have been recently reported [12] . Considered together, these data suggest that oncedaily dosing of darunavir/ritonavir might be used in patients with limited resistance to protease inhibitors. However, a pressing question is whether this strategy might be feasible in at least a subset of patients whose antiretroviral history is longer or more extensive.
In addition to the intrinsic antiretroviral activity and high genetic barrier of darunavir, pharmacological factors also have a role in the response to antiretroviral therapy with darunavir/ritonavir-based regimens. A significant relationship between darunavir trough concentration (C trough ) and the magnitude of the decrease in viral load at week 24 was reported by Sekar et al. [13] in a pharmacokinetic/pharmacodynamic analysis of the POWER studies. This relationship emerged mainly in patients harbouring viral strains with intermediate resistance to darunavir. Moreover, when resistance and pharmacokinetic data were combined into the inhibitory quotient (IQ), a stronger relationship between the darunavir IQ and the virological response to darunavir/ ritonavir-based salvage was evident. These findings were reproduced in another study in the clinical setting in which the long-term virological response to salvage therapy with darunavir/ritonavir-based regimens was related to the darunavir virtual IQ (vIQ), but not to darunavir concentrations or to the number of darunavir RAMs. This same study also identified a darunavir vIQ cutoff value of 1.5 for achieving viral suppression in the long term [14] .
On the basis of these findings, we hypothesized that treatment simplification to darunavir/ritonavir 900/100 mg once daily guided by the darunavir vIQ might be feasible in a subset of antiretroviral-experienced HIV-infected patients with sustained viral suppression while receiving salvage antiretroviral therapy including darunavir/ritonavir at the standard-of-care dosage of 600/100 mg twice daily. Our aim was to test whether this strategy might improve treatment tolerability and convenience, while maintaining viral suppression.
Methods

Study design
This open-label, randomized pilot study enrolled treatment-experienced HIV-infected patients receiving salvage antiretroviral therapy containing darunavir/ ritonavir 600/100 mg twice daily. Additional inclusion criteria were an undetectable viral load (HIV-1 RNA <50 copies/ml) for at least 12 weeks, a resistance test performed within the 4 weeks before starting antiretroviral therapy with darunavir/ritonavir and a darunavir vIQ >2 at screening. At enrolment, patients were randomized to receive darunavir/ritonavir 900/100 mg once daily in the morning (once-daily group) or to continue with the standard-of-care 600/100 mg twice-daily dose (twice-daily group). At the time this study was conducted darunavir was available only in 300 mg tablets, we therefore used the 900 mg instead of 800 mg dose of darunavir for patients allocated to the once-daily group. The other drugs in the antiretroviral background regimen remained unchanged. ) and darunavir and ritonavir plasma concentrations at the end of the dosing interval (C trough ), were determined.
The trial was performed according to the stipulations of the Declaration of Helsinki, the protocol was approved by the ethics committee of our hospital and patients gave informed consent before enrolment.
Pharmacokinetic analysis
Blood samples for darunavir and ritonavir C trough determinations were collected into 10 ml tubes containing potassium and ethylene diamine tetraacetic acid before the morning dose of darunavir/ritonavir. Plasma was isolated by centrifugation (3,200 g for 15 min) and stored at -20ºC until analysis. Darunavir and ritonavir concentrations were determined using HPLC with a photo diode array detector (HPLC-PDA 2996, Waters, Barcelona, Spain), according to a validated method. The analytical column was a NovaPak C18 3.9×150 mm with a NovaPak C18 guard column (Waters). The method involved liquid-liquid extraction of drug from plasma with methyl tert-butyl ether. The mobile phase consisted of a gradient elution with phosphate buffer in acetonitrile (pH 6.70). The method was linear over the range of 0.05-10.00 mg/l for both drugs (intra-and interday variation <10%). If the drug concentration was below the lower limit of quantitation, a concentration half of that value was assigned. Our laboratory subscribes to the external quality assurance programme organized by the Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology of Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands [15] .
Darunavir inhibitory quotient
Genetic sequences of HIV protease and reverse transcriptase genes within the 4 weeks prior to initiation of the darunavir/ritonavir regimen were recorded in each participant (TruGene HIV-1 genotyping kit; Siemens Medical Solutions, Barcelona, Spain). The virtual phenotype was obtained using vircoTYPE HIV-1, version 4.1 software (Virco BVBA, Mechelen, Belgium). The darunavir vIQ, calculated at each follow-up visit, was the ratio between the darunavir C trough and the fold change in the darunavir IC 50 in the virtual phenotype multiplied by the protein-bindingcorrected IC 50 of darunavir for protease-inhibitorresistant strains of HIV (0.55 mg/l) [16] . As a safety measure, if the darunavir vIQ was <1.5 in two consecutive determinations in patients allocated to the once-daily group, the darunavir/ritonavir dosage was switched back to 600/100 mg twice daily regardless of continued viral suppression.
Statistical analysis
The primary end point of the study was the percentage of patients without therapeutic failure at week 48. Failure was defined as a confirmed plasma HIV-1 RNA load >50 copies/ml, loss to follow-up or changes in the antiretroviral regimen other than switching the darunavir/ ritonavir dose to 600/100 mg twice daily. Secondary end points included the percentage of patients who stayed on the assigned study dose of darunavir/ritonavir at week 48, the incidence of adverse events or laboratory abnormalities leading to treatment discontinuation and changes in CD4 + T-cell count, lipid profile, liver enzyme levels or darunavir and ritonavir C trough during the follow-up. The analysis of these secondary end points was performed using a 'last observation carried forward' approach.
Data analysis was carried out using SPSS version 15.0 statistical software (Chicago, IL, USA). Continuous variables were described as mean (standard deviation [sd]) if they were normally distributed, and as median (interquartile range [IQR]) if not. Categorical data were summarized as percentages. Comparisons were performed using parametric or non-parametric tests, as appropriate, for continuous variables and the χ 2 test or Fisher exact test for percentages. The darunavir and ritonavir C trough were described using the geometric mean and 95% confidence interval (95% CI); comparisons between baseline and week 48 were performed using the geometric mean ratio (GMR) and the 95% CI. Differences were considered statistically significant at P<0.05.
Results
Out of 45 screened patients, 30 participants were finally randomized (once-daily group, n=15; twice-daily group, n=15). Seven patients were rejected because their darunavir vIQ was <2 and eight patients declined to participate.
The main patient characteristics were comparable in the two groups at baseline (Table 1) . Overall, patients had been treated with a mean of 11.6 (sd ±3.9) antiretroviral regimens including 5.3 (sd ±1.2) protease inhibitors before darunavir/ritonavir; 26 of the participants (86.7%) had received five or more protease inhibitors before enrolment. At baseline, the mean CD4 + T-cell count was 432 cells/ mm 3 (sd ±230) and the viral load had been undetectable for 86.7 weeks (sd ±71.7). Only 16 patients (53.3%), 8 in each study group, had documented darunavir RAMs [17] in the genotype performed before starting darunavir/ ritonavir therapy. The most frequent mutation was I84V (present in 10 patients), followed by the L33F mutation (in 5 patients) and the I50V and the L76V mutations (in 1 patient each). The median fold change in the darunavir IC 50 in the virtual phenotype was 1.2 (IQR 0.6-2.0) with only one patient, allocated to the twice-daily group, having a darunavir fold change >5. The mean number of active drugs in the background regimen was 1.7 (sd ±1.0) and seven (23.3%) patients were being treated with less than one active drug besides darunavir.
Virological and immunological outcomes
No patient developed virological failure during the follow-up; however, four patients, two in each group, prematurely discontinued darunavir/ritonavir therapy. Thus, the proportion of patients without therapeutic failure at week 48 was 13/15 (86.7%) in both study groups. There were no significant changes in the CD4 + T-cell count in either of the two groups during follow-up and the mean CD4 + T-cell count at week 48 was 584 cells/ mm 3 (sd ±310) in the once-daily group and 430 cells/ mm 3 (sd ±119) in the twice-daily group (P=0.093).
Safety and laboratory abnormalities
Four patients, two from each group, abandoned darunavir/ritonavir therapy before completing the study. Patients who discontinued treatment in the once-daily group included a patient who withdrew his informed consent to continue in the study at week 8 and another patient who was prescribed budesonide during the study and who developed Cushing's syndrome. Treatment discontinuations in the twice-daily group were due to a stroke in one participant, accompanied by serious difficulty in swallowing pills, and due to persistent grade 2 diarrhoea in another patient. Antiretroviral therapy in this patient was changed to darunavir/ ritonavir 900/100 mg once daily, with subsequent improvement in the clinical symptoms and a reduction in the number of stools/day. Table 2 summarizes liver enzyme levels and lipid profile changes at week 48. No significant changes in AST, ALT, total cholesterol, HDL, LDL cholesterol or triglyceride levels between baseline and week 48 were observed in either group. Nevertheless, although the proportion of patients with triglyceride levels >200 mg/ dl was similar in the two groups at baseline (33.3% in each group), at week 48 it was significantly lower in the once-daily group than in the twice-daily group (20.0% versus 57.1%; P=0.046).
Ritonavir and darunavir concentrations
The geometric mean (95% CI) ritonavir C trough in the once-daily group decreased from 0.31 mg/l (0.20-0.47) at baseline to 0.06 mg/l (0.04-0.09) at week 48 (GMR 0.19, 95% CI 0.10-0.36; P<0.001), whereas there were no changes during follow-up in the twice-daily group (GMR 1.11, 95% CI 0.72-1.73; P=0.617). As for darunavir concentrations, patients in the once-daily group showed a decrease in darunavir C trough from 3.09 mg/l (2.43-3.93) at baseline to 1.60 mg/l (1.25-2.04) at week 48 (GMR 0.52, 95% CI 0.37-0.73; P=0.001); there were no significant differences between baseline and week 48 in the twice-daily group (GMR 1.07, 95% CI 0.79-1.45; P=0.656). Consequently, eight (53.3%) patients in the once-daily group, but only three (20.0%) in the twice-daily group, had a darunavir vIQ <1.5 at any study visit. Moreover, three (20.0%) patients allocated to the once-daily group, two of whom harboured darunavir RAMs at baseline, had to switch back to the previous darunavir/ritonavir dose of 600/100 mg twice daily because they exhibited a darunavir vIQ persistently <1.5 during the follow-up. Therefore, the proportion of patients who remained on the originally assigned dosage at week 48 was 66.7% in the oncedaily group compared with 86.7% in the twice-daily group (P=0.195).
Discussion
The results of this exploratory study suggest that darunavir/ ritonavir at a dosage of 900/100 mg once daily might offer a valid treatment simplification approach for a subset of treatment-experienced HIVinfected patients receiving salvage antiretroviral therapy with standard dosages of darunavir/ritonavir 600/100 mg twice daily. This strategy might lead to improved tolerance of the treatment, while maintaining viral suppression.
A growing interest in once-daily administration of darunavir has been present since the early stages of the drug's clinical development [18] . Retrospective analyses of the POWER 1 and 2 studies as well as those from the ODIN randomized clinical trial [9, 10, 12] indicated that the efficacy of darunavir/ritonavir dosages of 600/100 mg twice daily and 800/100 mg once daily was comparable in patients with limited or no resistance to darunavir, as was the case for patients included in the present study. In line with these results, none of the participants in the present study developed virological failure during follow-up. The high efficacy of once-daily darunavir observed in our patients might be explained by its high genetic barrier to viral resistance, as well as its pharmacokinetic profile. As shown in a previous study of more than 200,000 viral isolates submitted for routine clinical resistance testing [2] , darunavir RAMs are uncommon in clinical practice, even in isolates with different levels of resistance to other protease inhibitors. In addition, pharmacokinetic data from the dose-finding period of the POWER studies showed that, although the patients treated with darunavir/ritonavir 800/100 mg once daily had lower darunavir C trough levels than those taking the 600/100 mg twice daily dosage, the drug concentrations remained far above the target for protease-resistant viral isolates [4] . Our results are consistent with these findings. Despite the extensive prior antiretroviral history of the patients in our study and the large number of protease inhibitor RAMs they harboured, we detected little resistance to darunavir, making our results not necessarily applicable to patients with higher degrees of resistance to darunavir.
A noteworthy observation is that the darunavir C trough in the once-daily group decreased by nearly half at week 48 compared with baseline, with a wide variability observed in both the darunavir C trough values and the magnitude of reduction after the switch from twicedaily to once-daily dosing. This makes the latter regimen less forgiving against the possibility of missed doses than twice-daily administration. Indeed, the darunavir/ ritonavir dosage had to be switched back to 600/100 mg twice daily for three patients in the once-daily arm, as their darunavir C trough values were considered to be inappropriately low during follow-up even though virological suppression was maintained. Apart from changes in the dosing regimen, changes in the patients' adherence pattern over time could also explain part of the variability observed in darunavir C trough and in their reduction during follow-up. Together, these results suggest that although a large proportion of treatmentexperienced patients might benefit from a once-daily darunavir/ritonavir dosing schedule, this strategy could only be considered for highly adherent patients. Moreover, when prescribing a once-daily darunavir/ritonavir dosage for treatment-experienced patients, it is highly advisable to monitor treatment adherence and darunavir concentrations and to interpret them in the light of resistance data.
Virological response to salvage therapy has been related to the degree of viral resistance to darunavir and, to a lesser extent, to plasma darunavir concentrations [13] . However, when darunavir concentrations were considered in relation to the degree of viral resistance, the IQ proved to be a better predictor of response than either parameter considered separately [13] . There are different ways to calculate the darunavir IQ depending on which assay is used and how viral resistance is assessed [16] . We chose the vIQ on the basis of data from a previous study in which we identified a darunavir vIQ cutoff of 1.5, which proved to predict long-term virological response in a cohort with similar characteristics to the one in the present study [14] . Other IQ calculations could be based on assessing viral resistance using phenotypic tests (phenotypic IQ) or relating darunavir concentrations to the number of darunavir RAMs (genotypic IQ) [16] . However, phenotypic assays might be expensive and time-consuming, and the genotypic IQ did not perform as well as the vIQ in a previous study comparing their predictive abilities [14] . Among potential benefits, once-daily dosing of darunavir might promote better treatment adherence in patients taking other once-daily antiretroviral drugs [19] . In addition, reducing the total daily dose of ritonavir needed to boost darunavir might ameliorate certain adverse events, such as gastrointestinal or metabolic disturbances. Reports from patients receiving darunavir/ritonavir once or twice daily in previous studies [8, 12, 20] showed lower rates of grade 2-4 diarrhoea and nausea, and lower total cholesterol or triglyceride concentrations in patients on the once-daily regimen. In the same line, our 48-week results in the present study also suggest that once-daily dosing is beneficial. One of our patients on the twice-daily regimen experienced clinical improvement in grade 2 diarrhoea when switched to the once-daily dose. Likewise, although the limited sample size of this study makes it necessary to interpret our results cautiously, the proportion of patients with triglyceride concentrations >200 mg/dl at the end of the study was lower in patients who had been switched to the once-daily regimen than in those who continued taking darunavir/ritonavir twice daily.
We are aware of potential limitations of the present study. Its exploratory design and limited sample size could have precluded the observation of small but significant differences in treatment outcomes between the two study groups. In addition, it is important to consider that patients included in the present study had low levels of resistance to darunavir and that complete viral suppression was considered an inclusion criterion. Consequently, our approach must be considered a treatment simplification strategy for patients with limited resistance to darunavir, and our results might not necessarily be reproducible in the context of patients with higher levels of resistance to darunavir or in viraemic patients starting a salvage regimen with darunavir/ritonavir at the once-daily dosage.
In conclusion, darunavir/ritonavir 900/100 mg once daily as a treatment simplification strategy guided by the darunavir vIQ in treatment-experienced HIVinfected patients receiving successful salvage therapy with darunavir/ritonavir 600/100 mg twice daily appears to be safe enough to be tested in adequately powered clinical trials.
